Cellares and City of Hope are partnering to evaluate automating CAR T manufacturing for glioblastoma brain cancer therapy.

Applied Cells Inc. and Immuneel Therapeutics Private Limited today announced that the companies have entered into a collaboration framework to jointly evaluate application of Applied Cells' MARS(R) ...

Autolus Therapeutics is working with Cellares to assess automated CAR T manufacturing to support rising demand for its ...

CAR-T therapy is a major advance in cancer care, but high costs and centralized global manufacturing limit access.

Not all patients respond well to chimeric antigen receptor (CAR) T cell therapies, which reprogram a patient’s own immune cells to recognize and attack cancer. A way to optimize these treatments is to ...

As demand for precision medicine accelerates, CAR T and CAR Treg cell therapies are emerging as crucial tools in the fight against cancer and autoimmune diseases. For Thomas Fellner, PhD, head of ...

Next-generation automation is closing the gap between curative science and real-world demand, enabling faster development, ...

Proof-of-concept manufacturing to be provided by Cellares for a key Lyell CAR T-cell therapy using Cellares' exclusive Cell Shuttle Collaboration to evaluate potential utilization of the Cell Shuttle ...

This review article highlights the transformative potential of in vivo CAR T cell therapy in addressing the limitations of traditional CAR T cell production. This innovative approach could ...

Machine-learning analysis identifies factors predicting T cell collection efficiency in CAR T-cell therapy for DLBCL patients. Higher blood volume, not higher circulating T-cell numbers, correlates ...

SHANGHAI and SAN FRANCISCO, Jan. 12, 2026 /PRNewswire/ -- Oricell Therapeutics Holdings Limited ("Oricell" or "the Company"), a global leader in innovative cancer immunotherapy, announced today the ...